Summary of Study ST002702

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001673. The data can be accessed directly via it's Project DOI: 10.21228/M8FQ4P This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002702
Study TitleA targeted metabolomics approach for sepsis-induced ARDS and its subphenotypes
Study SummaryAcute respiratory distress syndrome (ARDS) is etiologically and clinically a heterogeneous disease. Its diagnostic characteristics and subtype classification, and the application of these features to treatment, have been of considerable interest. Metabolomics is becoming important for identifying ARDS biology and distinguishing its subtypes. This study aimed to identify metabolites that could distinguish sepsis-induced ARDS patients from non-ARDS controls, using a targeted metabolomics approach, and to identify whether sepsis-induced direct and sepsis-induced indirect ARDS are metabolically distinct groups, and if so, confirm their metabolites and associated pathways.
Institute
Asan Medical Center
Last NameYoo
First NameHyun Ju
Address88, Olympic-ro 43-gil, Songpa-gu
Emaild131108@ulsan.ac.kr
Phone0230104029
Submit Date2023-05-15
Raw Data AvailableYes
Raw Data File Type(s)OTHER
Analysis Type DetailGC-MS/LC-MS
Release Date2023-07-06
Release Version1
Hyun Ju Yoo Hyun Ju Yoo
https://dx.doi.org/10.21228/M8FQ4P
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR001673
Project DOI:doi: 10.21228/M8FQ4P
Project Title:A targeted metabolomics approach for sepsis-induced ARDS and its subphenotypes
Project Summary:Acute respiratory distress syndrome (ARDS) is etiologically and clinically a heterogeneous disease. Its diagnostic characteristics and subtype classification, and the application of these features to treatment, have been of considerable interest. Metabolomics is becoming important for identifying ARDS biology and distinguishing its subtypes. This study aimed to identify metabolites that could distinguish sepsis-induced ARDS patients from non-ARDS controls, using a targeted metabolomics approach, and to identify whether sepsis-induced direct and sepsis-induced indirect ARDS are metabolically distinct groups, and if so, confirm their metabolites and associated pathways.
Institute:Asan Medical Center
Last Name:Yoo
First Name:Hyun Ju
Address:88, Olympic-ro 43-gil, Songpa-gu
Email:d131108@ulsan.ac.kr
Phone:0230104029

Subject:

Subject ID:SU002807
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Factor
SA270931Normal_1_S1PControl
SA270932D_Serum_2_AminoAcidsControl
SA270933D_Serum_4_AminoAcidsControl
SA270934Normal_30_FFAControl
SA270935D_Serum_3_AminoAcidsControl
SA270936Normal_28_FFAControl
SA270937Normal_25_FFAControl
SA270938Normal_26_FFAControl
SA270939Normal_27_FFAControl
SA270940D_Serum_5_AminoAcidsControl
SA270941Normal_29_FFAControl
SA270942D_Serum_6_AminoAcidsControl
SA270943D_Serum_12_AminoAcidsControl
SA270944D_Serum_13_AminoAcidsControl
SA270945D_Serum_14_AminoAcidsControl
SA270946D_Serum_15_AminoAcidsControl
SA270947D_Serum_11_AminoAcidsControl
SA270948D_Serum_10_AminoAcidsControl
SA270949D_Serum_7_AminoAcidsControl
SA270950D_Serum_8_AminoAcidsControl
SA270951D_Serum_9_AminoAcidsControl
SA270952Normal_24_FFAControl
SA270953Normal_23_FFAControl
SA270954Normal_8_FFAControl
SA270955Normal_9_FFAControl
SA270956Normal_10_FFAControl
SA270957Normal_11_FFAControl
SA270958Normal_7_FFAControl
SA270959Normal_6_FFAControl
SA270960Normal_3_FFAControl
SA270961Normal_4_FFAControl
SA270962Normal_5_FFAControl
SA270963Normal_12_FFAControl
SA270964Normal_13_FFAControl
SA270965Normal_19_FFAControl
SA270966Normal_20_FFAControl
SA270967Normal_21_FFAControl
SA270968Normal_22_FFAControl
SA270969Normal_18_FFAControl
SA270970Normal_17_FFAControl
SA270971Normal_14_FFAControl
SA270972Normal_15_FFAControl
SA270973Normal_16_FFAControl
SA270974D_Serum_16_AminoAcidsControl
SA270975D_Serum_18_AminoAcidsControl
SA270976D_Serum_16_EnergyMetabolismControl
SA270977D_Serum_17_EnergyMetabolismControl
SA270978D_Serum_18_EnergyMetabolismControl
SA270979D_Serum_19_EnergyMetabolismControl
SA270980D_Serum_15_EnergyMetabolismControl
SA270981D_Serum_14_EnergyMetabolismControl
SA270982D_Serum_10_EnergyMetabolismControl
SA270983D_Serum_11_EnergyMetabolismControl
SA270984D_Serum_12_EnergyMetabolismControl
SA270985D_Serum_13_EnergyMetabolismControl
SA270986D_Serum_20_EnergyMetabolismControl
SA270987D_Serum_21_EnergyMetabolismControl
SA270988D_Serum_27_EnergyMetabolismControl
SA270989D_Serum_28_EnergyMetabolismControl
SA270990D_Serum_29_EnergyMetabolismControl
SA270991D_Serum_30_EnergyMetabolismControl
SA270992D_Serum_26_EnergyMetabolismControl
SA270993D_Serum_25_EnergyMetabolismControl
SA270994D_Serum_22_EnergyMetabolismControl
SA270995D_Serum_23_EnergyMetabolismControl
SA270996D_Serum_24_EnergyMetabolismControl
SA270997D_Serum_9_EnergyMetabolismControl
SA270998D_Serum_8_EnergyMetabolismControl
SA270999D_Serum_23_AminoAcidsControl
SA271000D_Serum_24_AminoAcidsControl
SA271001D_Serum_25_AminoAcidsControl
SA271002D_Serum_26_AminoAcidsControl
SA271003D_Serum_22_AminoAcidsControl
SA271004D_Serum_21_AminoAcidsControl
SA271005Normal_2_FFAControl
SA271006D_Serum_19_AminoAcidsControl
SA271007D_Serum_20_AminoAcidsControl
SA271008D_Serum_27_AminoAcidsControl
SA271009D_Serum_28_AminoAcidsControl
SA271010D_Serum_4_EnergyMetabolismControl
SA271011D_Serum_5_EnergyMetabolismControl
SA271012D_Serum_6_EnergyMetabolismControl
SA271013D_Serum_7_EnergyMetabolismControl
SA271014D_Serum_3_EnergyMetabolismControl
SA271015D_Serum_2_EnergyMetabolismControl
SA271016D_Serum_29_AminoAcidsControl
SA271017D_Serum_30_AminoAcidsControl
SA271018D_Serum_1_EnergyMetabolismControl
SA271019D_Serum_17_AminoAcidsControl
SA271020D_Serum_1_AminoAcidsControl
SA271021Normal_12_S1PControl
SA271022Normal_11_S1PControl
SA271023Normal_13_S1PControl
SA271024Normal_14_S1PControl
SA271025Normal_16_S1PControl
SA271026Normal_15_S1PControl
SA271027Normal_10_S1PControl
SA271028Normal_9_S1PControl
SA271029Normal_5_S1PControl
SA271030Normal_4_S1PControl
Showing page 1 of 4     Results:    1  2  3  4  Next     Showing results 1 to 100 of 360

Collection:

Collection ID:CO002800
Collection Summary:This study retrospectively analyzed the samples of the ASAN sepsis registry obtained from March 2011 to February 2018, along with the non-ARDS controls. This study was approved by the Asan Institutional Review Board (IRB No. 2019-1017).
Sample Type:Blood (serum)

Treatment:

Treatment ID:TR002816
Treatment Summary:Human serum was stored at deep freezer until analysis. For metabolome analysis, human serum was prepared to extract metabolites using conventional liquid-liquid exrtaction method known as BD method.

Sample Preparation:

Sampleprep ID:SP002813
Sampleprep Summary:Sample solutions were prepared by using commonly used liquid-liquid extaction procedure known as Bligh/Dyer mthod with minor modifications.(Can.J.Biochem.Physiol. 37:911-917) Briefly, 400 μL of chloroform/methanol (1/2, v/v) was added to each sample solution and mixed well. The solution was centrifuged for 15 min at 14000 rpm. After centrifugation, a thick precipitate containing macromolecules was found between the aqueous upper layer and the organic lower layer. Polar metabolites were contained in the upper aqueous phase. The collected volume from each layer were generally the same, however sometimes any specific sample had thicker interface between organic and aqueous layer, which resulted in little variation of the recovered volumes. However, internal standards added prior to sample preparation should correct this variation. The aqueous phases were dried under vacuum and stored at -20℃ until further analysis. The dried matter from the aqueous solutions was reconstituted with 50 μL of H2O/MeOH (50/50 v/v) prior to liquid chromatography–tandem mass spectrometry (LC-MS/MS) analysis. For amino acids, 10 μL out of the total 50 μL reconstituted aqueous phase was used for chemical derivatization of amino acids using phenylisothiocyanate.For S1P and free fatty acids, separate serum samples were used. Details can be found in attached method file.

Combined analysis:

Analysis ID AN004379 AN004380 AN004381 AN004382
Analysis type MS MS MS MS
Chromatography type Reversed phase Reversed phase Reversed phase GC
Chromatography system Agilent 1290 Agilent 1290 Thermo Dionex Ultimate 3000 Agilent 7890A
Column Phenomenex Synergi Fusion-RP (100 x 4.6mm,4um) Agilent ZORBAX Eclipse Plus C18 (50 x 2.1mm,1.8um) Phenomenex Jupiter C18 (150 x 2mm,5um) Agilent HP5-MS (30m x 0.25mm, 0.25 um)
MS Type ESI ESI ESI EI
MS instrument type QTRAP QTRAP Orbitrap Single quadrupole
MS instrument name ABI Sciex 5500 QTrap ABI Sciex 5500 QTrap Thermo LTQ XL Agilent 5975C
Ion Mode NEGATIVE POSITIVE NEGATIVE POSITIVE
Units nM uM ug/uL area ratio

Chromatography:

Chromatography ID:CH003284
Chromatography Summary:Metabolites related to energy metabolism
Instrument Name:Agilent 1290
Column Name:Phenomenex Synergi Fusion-RP (100 x 4.6mm,4um)
Column Temperature:23
Flow Gradient:Hold at 0% B for 5 min, 0% to 90% B for 2 min, hold at 90% for 8 min, 90% to 0% B for 1 min, then hold at 0% B for 9 min
Flow Rate:70 μL/min except for 140 μL/min during minutes 7–15
Solvent A:100% water; 5mM ammonium acetate
Solvent B:100% methanol; 5 mM ammonium acetate
Chromatography Type:Reversed phase
  
Chromatography ID:CH003285
Chromatography Summary:Amino acids
Instrument Name:Agilent 1290
Column Name:Agilent ZORBAX Eclipse Plus C18 (50 x 2.1mm,1.8um)
Column Temperature:50
Flow Gradient:Hold at 0% B for 0.5 min, 0–95% B for 5 min, 95% B for 1 min, and 95–0% B for 0.5 min, then hold at 0% B for 2.5 min
Flow Rate:500 μL/min
Solvent A:100% water; 0.2% formic acid
Solvent B:100% acetonitrile; 0.2% formic acid
Chromatography Type:Reversed phase
  
Chromatography ID:CH003286
Chromatography Summary:S1P
Instrument Name:Thermo Dionex Ultimate 3000
Column Name:Phenomenex Jupiter C18 (150 x 2mm,5um)
Column Temperature:35°C
Flow Gradient:10% B for 0 min, 10–90% B for 5 min, 90% B for 10 min, 90–10% B for 0.1 min, and 10% B for 4.9 min
Flow Rate:300 μL/min
Solvent A:100% water; 0.1% formic acid
Solvent B:100% methanol; 0.1% formic acid
Chromatography Type:Reversed phase
  
Chromatography ID:CH003287
Chromatography Summary:Free fatty acids (FFA)
Instrument Name:Agilent 7890A
Column Name:Agilent HP5-MS (30m x 0.25mm, 0.25 um)
Column Temperature:-
Flow Gradient:-
Flow Rate:-
Solvent A:-
Solvent B:-
Chromatography Type:GC

MS:

MS ID:MS004128
Analysis ID:AN004379
Instrument Name:ABI Sciex 5500 QTrap
Instrument Type:QTRAP
MS Type:ESI
MS Comments:Analyst1.5.2
Ion Mode:NEGATIVE
  
MS ID:MS004129
Analysis ID:AN004380
Instrument Name:ABI Sciex 5500 QTrap
Instrument Type:QTRAP
MS Type:ESI
MS Comments:Analyst1.5.2
Ion Mode:POSITIVE
  
MS ID:MS004130
Analysis ID:AN004381
Instrument Name:Thermo LTQ XL
Instrument Type:Orbitrap
MS Type:ESI
MS Comments:Xcalibur, SRM
Ion Mode:NEGATIVE
  
MS ID:MS004131
Analysis ID:AN004382
Instrument Name:Agilent 5975C
Instrument Type:Single quadrupole
MS Type:EI
MS Comments:Chemstatation, SRM
Ion Mode:POSITIVE
  logo